Jeep unveils 2024 Wrangler SUV in next stage of off-road sales battle with Ford Bronco

Jeep unveils 2024 Wrangler SUV in next stage of off-road sales battle with Ford Bronco


2024 Jeep Wrangler Rubicon X 4xe

Jeep

Jeep is updating its flagship Wrangler SUV with more capability, technologies and features as it battles for off-road buyers against Ford’s newer Bronco.

The 2024 Jeep Wrangler features an evolutionary exterior design, which is typical for the quintessential SUV, and a redesigned interior that includes additional safety, convenience and tech features such as a 12.3-inch center control screen.

“Today, we are raising the bar once again by combining the most capable Wrangler to date, with more technology, comfort and safety features,” Jeep CEO Christian Meunier, said in a release pegged to the vehicle’s reveal Wednesday at the New York International Auto Show.

In addition to the interior upgrades, the 2024 Wrangler will offer additional off-road features such as larger tires and an 8,000-pound-capacity warn winch. It also adds many additional safety features and new roof options similar to what Ford’s Bronco has offered since it arrived to market in 2021.

2024 Jeep Wrangler Rubicon 392 (left) and Wrangler Rubicon X 4xe

Jeep

Jeep, specifically with the Wrangler, has long dominated the off-road SUV segment. Many competitors from General Motors, Ford Motor and others have come and gone, but the Wrangler has remained the industry-leader.

However, the Ford Bronco has been gaining momentum — following some launch and supply chain problems. Ford sold 117,057 Broncos last year. That compares to 181,409 Jeep Wranglers sold. The sales gap between the two significantly narrowed during the first quarter of this year, however, to fewer than 2,000 vehicles.

A key differentiator attracting new customers to the Wrangler is a plug-in hybrid electric version, or PHEV, that the brand calls “4xe,” a play on the brand’s “4×4” off-road reputation combined with electrification.

2024 Jeep Wrangler interior

Jeep

The Wrangler 4xe has been the best-selling PHEV in the U.S. for the past two years, according to the company. The automaker hopes to further expand those sales buy offering 4xe on a lower-priced model called the Wrangler Sport S.

“I think we shocked the world a little bit with Wrangler being the number-one selling plug-in hybrid now two years in a row,” Jim Morrison, head of Jeep in North America, said

during a media event ahead of the SUV’s reveal. “For us, I’m pretty sure that competition didn’t see that coming. But it’s a really good Jeep, and it’s electrified.”

The 2024 Jeep Wrangler will be available in Sport, Willys, Sahara, High Altitude, Rubicon and Rubicon392 models. Ordering is open now, and vehicles will start to arrive in U.S. Jeep dealerships later in 2023, the company said.

A Jeep spokesman said pricing for the 2024 Wrangler will be announced closer to the vehicle’s launch. Current Wrangler starting prices range from about $31,000 for an entry-level model to more than $82,000 for a V-8-powered Rubicon 392 model.

2024 Jeep Wrangler Willys

Jeep



Source

Inside the booming business of wellness third spaces and membership clubs
Business

Inside the booming business of wellness third spaces and membership clubs

A few years ago, Grace Guo began to crave places in New York City where hanging out with friends didn’t have to involve alcohol. Newly sober and surrounded by friends who also chose not to drink, Guo said she wanted alternatives to the typical social scene. After some research, she landed on Bathhouse and Othership: […]

Read More
FDA vaccine head will step down in April after string of controversial decisions
Business

FDA vaccine head will step down in April after string of controversial decisions

The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the […]

Read More
FDA reversals leave investors worrying about the fates of other experimental drugs
Business

FDA reversals leave investors worrying about the fates of other experimental drugs

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration.  The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]

Read More